Genomic Medicine Laboratory, Experimental Research Center, Hospital de Clínicas de Porto Alegre (HCPA), Rua Ramiro Barcelos, 2350, 90035-903 Porto Alegre, RS, Brazil.
Virchows Arch. 2013 Jul;463(1):17-22. doi: 10.1007/s00428-013-1439-8. Epub 2013 Jun 21.
A few studies have reported phyllodes tumors (PT) of the breast with germline TP53 mutations. Given this potential association and the high frequency of the TP53 p.R337H in southern and southeastern Brazil, the aim of this study was to assess whether p.R337H occurs among women diagnosed with such rare tumors in this region. Benign, borderline, and malignant breast PT were retrieved from eight pathology laboratories, and DNA was extracted from tumor tissue to perform p.R337H analysis. Overall, 128 cases classified as benign, 7 as borderline, and 13 as malignant PT were included in the study. The TP53 p.R337H mutation was identified in tumor cells of eight (5.4 %) cases. Analysis of DNA from non-tumoral tissue was possible in two of these, and both were p.R337H carriers in the germline. In addition, haplotype analysis was done in these two p.R337H carriers showing the presence of the founder haplotype previously reported in Brazilian mutation-positive individuals. Mutation frequency was significantly higher among malignant (3 of 13; 23 %) compared to benign tumors (5 of 128; 3.4 %) (p = 0.004). Mean age at PT diagnosis was not significantly different between mutation carriers and non-carriers. However, when subgroups where analyzed, the difference in age at diagnosis of carriers versus non-carriers within the group of benign tumors reached borderline significance. Our findings reinforce previous evidence that TP53 mutations have an important role in the development of both benign and malignant PT of the breast.
一些研究报道了乳腺叶状肿瘤(PT)存在种系 TP53 突变。鉴于这种潜在的关联以及 TP53 p.R337H 在巴西南部和东南部的高频率,本研究旨在评估在该地区诊断为这种罕见肿瘤的女性中是否存在 p.R337H。从八个病理实验室中检索到良性、交界性和恶性乳腺 PT,并从肿瘤组织中提取 DNA 进行 p.R337H 分析。共有 128 例良性、7 例交界性和 13 例恶性 PT 纳入研究。在 8 例(5.4%)肿瘤细胞中鉴定出 TP53 p.R337H 突变。在其中的 2 例中可以分析非肿瘤组织的 DNA,并且这 2 例均为种系中的 p.R337H 携带者。此外,对这两个 p.R337H 携带者进行了单倍型分析,显示存在先前在巴西突变阳性个体中报道的创始单倍型。恶性肿瘤(13 例中的 3 例;23%)的突变频率明显高于良性肿瘤(128 例中的 5 例;3.4%)(p=0.004)。PT 诊断时的平均年龄在突变携带者和非携带者之间没有显著差异。然而,当对亚组进行分析时,良性肿瘤组中携带者与非携带者的诊断年龄差异达到边缘显著。我们的发现进一步证实了先前的证据,即 TP53 突变在乳腺良性和恶性叶状肿瘤的发生中具有重要作用。